scholarly journals Imaging features of breast cancer molecular subtypes: An Updated Review of the Literature

2022 ◽  
Vol 5 (1) ◽  
pp. 92-103
Author(s):  
Ebtsam Ahmed Mohammed ◽  
Mohammad Tharwat Mahmoud Solyman ◽  
Nagham Nabil Omar ◽  
Nahla Mohamed Ali Hasan
Keyword(s):  
Breast Cancer ◽  
Molecular Subtypes ◽  
Imaging Features ◽  
Review Of The Literature

Correlation between imaging features and molecular subtypes of breast cancer in young women (≤30 years old)

2020 ◽  
Vol 38 (11) ◽  
pp. 1062-1074
Author(s):  
Junlin Huang ◽  
Qing Lin ◽  
Chunxiao Cui ◽  
Jie Fei ◽  
Xiaohui Su ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Young Women ◽  
Molecular Subtypes ◽  
Imaging Features

scholarly journals Molecular Subtypes of Breast Cancer: A Review for Breast Radiologists

2020 ◽  
Author(s):  
Karen S Johnson ◽  
Emily F Conant ◽  
Mary Scott Soo
Keyword(s):  
Breast Cancer ◽  
Molecular Subtypes ◽  
Disease Free Survival ◽  
Response To Treatment ◽  
Her2 Status ◽  
Imaging Features ◽  
Luminal A ◽  
Luminal B ◽  
Her2 Breast Cancer ◽  
Er Expression

Abstract Gene expression profiling has reshaped our understanding of breast cancer by identifying four molecular subtypes: (1) luminal A, (2) luminal B, (3) human epidermal growth factor receptor 2 (HER2)-enriched, and (4) basal-like, which have critical differences in incidence, response to treatment, disease progression, survival, and imaging features. Luminal tumors are most common (60%–70%), characterized by estrogen receptor (ER) expression. Luminal A tumors have the best prognosis of all subtypes, whereas patients with luminal B tumors have significantly shorter overall and disease-free survival. Distinguishing between these tumors is important because luminal B tumors require more aggressive treatment. Both commonly present as irregular masses without associated calcifications at mammography; however, luminal B tumors more commonly demonstrate axillary involvement at diagnosis. HER2-enriched tumors are characterized by overexpression of the HER2 oncogene and low-to-absent ER expression. HER2+ disease carries a poor prognosis, but the development of anti-HER2 therapies has greatly improved outcomes for women with HER2+ breast cancer. HER2+ tumors most commonly present as spiculated masses with pleomorphic calcifications or as calcifications alone. Basal-like cancers (15% of all invasive breast cancers) predominate among “triple negative” cancers, which lack ER, progesterone receptor (PR), and HER2 expression. Basal-like cancers are frequently high-grade, large at diagnosis, with high rates of recurrence. Although imaging commonly reveals irregular masses with ill-defined or spiculated margins, some circumscribed basal-like tumors can be mistaken for benign lesions. Incorporating biomarker data (histologic grade, ER/PR/HER2 status, and multigene assays) into classic anatomic TNM staging can better inform clinical management of this heterogeneous disease.

Imaging features of automated breast volume scanner: Correlation with molecular subtypes of breast cancer

2017 ◽  
Vol 86 ◽  
pp. 267-275 ◽  
Author(s):  
Feng-Yang Zheng ◽  
Qing Lu ◽  
Bei-Jian Huang ◽  
Han-Sheng Xia ◽  
Li-Xia Yan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Molecular Subtypes ◽  
Imaging Features ◽  
Breast Volume ◽  
Automated Breast Volume Scanner

scholarly journals Is There a Correlation between Multiparametric Assessment in Ultrasound and Intrinsic Subtype of Breast Cancer?

2021 ◽  
Vol 10 (22) ◽  
pp. 5394
Author(s):  
Magdalena Gumowska ◽  
Joanna Mączewska ◽  
Piotr Prostko ◽  
Katarzyna Roszkowska-Purska ◽  
Katarzyna Dobruch-Sobczak
Keyword(s):  
Breast Cancer ◽  
Molecular Subtypes ◽  
Treatment Strategies ◽  
Growth Factor Receptor ◽  
Molecular Profile ◽  
Her2 Overexpression ◽  
Imaging Features ◽  
Luminal A ◽  
Luminal B ◽  
Post Surgery

Molecular profile of breast cancer provides information about its biological activity, prognosis and treatment strategies. The purpose of our study was to investigate the correlation between ultrasound features and molecular subtypes of breast cancer. From June 2019 to December 2019, 86 patients (median age 57 years; range 32–88) with 102 breast cancer tumors were included in the study. The molecular subtypes were classified into five types: luminal A (LA), luminal B without HER2 overexpression (LB HER2−), luminal B with HER2 overexpression (LB HER2+), human epidermal growth factor receptor 2 positive (HER2+) and triple negative breast cancer (TNBC). Histopathological verification was obtained in core biopsy or/and post-surgery specimens in all cases. Univariate logistic regression analysis was performed to assess the association between the subtypes and ultrasound imaging features. Experienced radiologists assessed lesions according to the BIRADS-US lexicon. The ultrasound scans were performed with a Supersonic Aixplorer and Supersonix. Based on histopathological verification, the rates of LA, LB HER2−, LB HER2+, HER2+, and TNBC were 33, 17, 17, 16, 19, respectively. Both LB HER2+ and HER2+ subtypes presented higher incidence of calcification (OR = 3.125, p = 0.02, CI 0.0917–5.87) and HER2+ subtype presented a higher incidence of posterior enhancement (OR = 5.75, p = 0.03, CI 1.2257–32.8005), compared to other subtypes. The calcifications were less common in TNBC (OR = 0.176, p = 0.0041, CI 0.0469–0.5335) compared to other subtypes. There were no differences with regard to margin, shape, orientation, elasticity values and vascularity among five molecular subtypes. Our results suggest that there is a correlation between ultrasonographic features assessed according to BIRADS-US lexicon and BC subtypes with HER2 overexpression (both LB HER2+ and HER2+). It may be useful for identification of these aggressive subtypes of breast cancer.

Sign in / Sign up

Export Citation Format

Share Document